ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 109,96
0,16%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Clearside Biomedical Inc (CLSD)

  7. Clearside Biomedical Inc (CLSD) Actualités

CLSD Clearside Biomedical Inc

1,1705
-0,0595 (-4,84%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Clearside Biomedical Inc CLSD NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0595 -4,84% 1,1705 06:00:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,23 1,18 1,24 1,19 1,23
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
12/6/202413:05GLOBEClearside Biomedical’s Leadership in Suprachoroidal Delivery..
21/5/202413:05GLOBEClearside Biomedical Announces Publication of Consensus..
10/5/202422:31EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/5/202422:10EDGAR2Form 8-K - Current report
09/5/202422:05GLOBEClearside Biomedical Announces First Quarter 2024 Financial..
08/5/202422:15GLOBEClearside Biomedical to Participate in Fireside Chat at the..
30/4/202413:05GLOBEClearside Biomedical to Report First Quarter 2024 Financial..
16/4/202413:05GLOBEClearside Biomedical Appoints Seasoned Biotechnology..
02/4/202413:05GLOBEClearside Biomedical to Participate in Fireside Chat at the..
18/3/202412:05GLOBEClearside Biomedical Appoints Victor Chong, M.D., MBA as..
12/3/202421:05GLOBEClearside Biomedical Announces Fourth Quarter and Full Year..
29/2/202413:05GLOBEClearside Biomedical to Report Fourth Quarter and Full Year..
08/2/202423:05EDGAR2Form 8-K - Current report
08/2/202422:52EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/2/202414:00GLOBEClearside Biomedical Announces Pricing of $15 Million..
01/2/202422:01EDGAR2Form 8-K - Current report
20/1/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202421:04EDGAR2Form 144 - Report of proposed sale of securities
28/12/202322:10EDGAR2Form 8-K - Current report
14/12/202313:05GLOBEClearside Biomedical Reports Significant Progress in ODYSSEY..
13/11/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:10EDGAR2Form 8-K - Current report
13/11/202322:05GLOBEClearside Biomedical Announces Third Quarter 2023 Financial..
08/11/202313:05GLOBEClearside Biomedical to Participate in Fireside Chat at the..
07/11/202322:20GLOBEClearside Biomedical’s Versatile Suprachoroidal Injection..
03/11/202317:01EDGAR2Form 8-K - Current report
03/11/202317:00GLOBEBioCryst and Clearside Biomedical Enter Partnership to..
02/11/202312:05GLOBEClearside Biomedical Announces Presentations at the American..
01/11/202312:05GLOBEClearside Biomedical Completes Recruitment in ODYSSEY Phase..
31/10/202312:05GLOBEClearside Biomedical to Report Third Quarter 2023 Financial..
16/10/202313:05GLOBEClearside Biomedical Positive OASIS and Extension Study Data..
04/10/202315:00GLOBEClearside Biomedical Announces Advancement of XIPERE® in..
03/10/202322:35GLOBEClearside Biomedical to Participate in a Panel Discussion at..
29/9/202322:46EDGAR2Form 8-K - Current report
25/9/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/9/202322:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202313:05GLOBEClearside Biomedical to Participate in Panel Discussion at..
14/9/202300:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202322:11EDGAR2Form 8-K - Current report
14/8/202322:05GLOBEClearside Biomedical Announces Second Quarter 2023 Financial..
02/8/202322:30GLOBEClearside Biomedical to Participate in Upcoming Investor..
01/8/202313:05GLOBEClearside Biomedical to Report Second Quarter 2023 Financial..
31/7/202313:05GLOBEClearside Biomedical Highlights Excellent Safety Profile of..
20/7/202313:05GLOBEClearside Biomedical’s Suprachoroidal Injection Platform to..
17/7/202313:05GLOBEClearside Biomedical Announces Enrollment of Multiple..
11/7/202322:05GLOBEClearside Biomedical CEO George Lasezkay to Present at the..
10/7/202313:05GLOBEClearside Biomedical Asia-Pacific Partner Arctic Vision..

Dernières Valeurs Consultées

NASDAQ
CLSD
Clearside Biomedical
ASX
NCMLOT
TG
A280QR
Commonwealth of Australia
EU
MLAF
Compagnie Generale des E...
BIT
P1T6R1
BNP Paribas Issuance
TSXV
VQS
VIQ Solutions
LSE
52LZ
Sthn.pac.42b1ca
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés